Willis-Knighton Health System Serves as Trial Site for Pfizer’s Post-Exposure Prophylactic

Willis-Knighton Health System Serves as Trial Site for Pfizer’s Post-Exposure Prophylactic

A Louisiana-based, not-for-profit, locally-operated healthcare organization expands its clinical trials with a call for participation in a clinical trial investigating whether an oral medication can prevent COVID-19 in people who have contracted the illness from a household contact. One of nearly 400 trial sites across America involved with this study, Willis-Knighton Health System participates in the household contacts study investigating the efficacy of Pfizer’s antiviral drug PF-07321332 and Ritonavir.

The Study

Called “A Post-Exposure Prophylaxis Study of PF-07321332/Ritonavir in Adult Household Contacts of an Individual with Symptomatic COVID-19” (NCT05047601) the Phase 3 study evaluates the efficacy and safety of the Pfizer antiviral called PF-07321332 plus ritonavir as post-exposure prophylaxis (PeP) for adult household contacts of a patient with COVID-19.

Targeting 2,634 participants, the study started in September and runs until the end of the year. Pfizer is competing with Merck and their antiviral for the huge market concerning the treatment of mild-to-moderate COVID-19 as a post-exposure prophylactic. The primary endpoint of this study focuses o...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee